Bivalirudin vs Dulaglutide
Overview
Bivalirudin is primarily a cardiovascular peptide, while Dulaglutide is used for weight management & metabolic.
This page compares Bivalirudin and Dulaglutide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Bivalirudin | Dulaglutide | |
|---|---|---|
| Category | Cardiovascular | Weight Management & Metabolic |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion | 0.75-4.5 mg |
| Frequency | Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours | weekly |
| Reported benefits | Anticoagulation during PCI and PTCA, anticoagulation in HIT/HITTS patients undergoing PCI, reduced major bleeding versus heparin plus glycoprotein IIb/IIIa inhibitor, predictable pharmacokinetics without need for antithrombin cofactor, rapid offset of anticoagulation due to short half-life, inhibition of both circulating and clot-bound thrombin | Blood sugar control, weight management, cardiovascular benefits |
| Reported side effects | Bleeding (most common, including access-site and retroperitoneal), acute stent thrombosis (early, within 24 hours), back pain, nausea, headache, hypotension, injection-site pain, hypersensitivity reactions, thrombocytopenia (rare) | Nausea, diarrhea, injection site reactions |
Key differences
Primary use. Bivalirudin is categorised under Cardiovascular, while Dulaglutide falls under Weight Management & Metabolic. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Bivalirudin: FDA-approved. Dulaglutide: FDA-approved.
Dosing. Bivalirudin is typically dosed at 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion (Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours). Dulaglutide is typically dosed at 0.75-4.5 mg (weekly).
Can you stack them?
Some protocols combine peptides, but stacking Bivalirudin and Dulaglutide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Bivalirudin and Dulaglutide?
- Bivalirudin is primarily a cardiovascular peptide, while Dulaglutide is used for weight management & metabolic. Bivalirudin is FDA-approved for one or more indications, whereas Dulaglutide is FDA-approved for one or more indications.
- What is Bivalirudin used for?
- FDA-approved synthetic peptide direct thrombin inhibitor used for anticoagulation during PCI, including in HIT patients.
- What is Dulaglutide used for?
- Weekly GLP-1 (Trulicity).
- Can you take Bivalirudin and Dulaglutide together?
- Some users combine peptides within a single protocol, but stacking Bivalirudin and Dulaglutide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Bivalirudin or Dulaglutide FDA-approved?
- Bivalirudin is FDA-approved for one or more indications. Dulaglutide is FDA-approved for one or more indications.
Read the full articles
- Bivalirudin — full monograph: mechanism, research, dosing & references
- Dulaglutide — full monograph: mechanism, research, dosing & references